Breaking News Instant updates and real-time market news.

EFX

Equifax

$124.97

-17.755 (-12.44%)

, TRU

TransUnion

$47.34

-2.05 (-4.15%)

12:44
09/08/17
09/08
12:44
09/08/17
12:44

On The Fly: Top stock stories at midday

Stocks began the session with modest losses but saw their lows a short time after the open. Investors have been closely watching the approach of Hurricane Irma and trying to gauge the economic impact of it. NY Fed President Bill Dudley, in an interview on CNBC, said that historically the short-term impact of hurricanes is negative but over the longer-term they add to economic activity. Oil prices are lower by roughly 2 % as demand is expected to be impacted by the storm. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 0.6% in July, while sales fell 0.1%, both weaker than forecast. In Asia, China's exports fell short of expectations in August, rising 5.5%, while imports were stronger than expected with an increase of 13.3%. COMPANY NEWS: Equifax (EFX), operator of one of the "big three" credit bureaus, announced that criminals exploited a website application vulnerability to gain access to certain files, creating a cybersecurity breach potentially impacting approximately 143M U.S. consumers. The information accessed includes names, Social Security numbers and birth dates, but credit card numbers for approximately 209,000 U.S. consumers were also taken, the company stated. Equifax discovered the unauthorized access on July 29 of this year and "acted immediately to stop the intrusion," it added. Some questions have been raised in the wake of the news about $1.8M of stock sales by three company insiders just a few days after the breach discovery, but the company claims the incident was initially investigated by a select group and not widely communicated. Equifax shares plunged 12% following the news, while peer TransUnion (TRU) slid 4% in sympathy. MAJOR MOVERS: Among the notable gainers was NewLink Genetics (NLNK), which rose for a second straight day after the company announced updated data from an ongoing Phase 2 study of indoximod. NewLink was upgraded today to Buy at Jefferies, as analyst Biren Amin sees additional share upside post the ongoing Phase II trial update given indoximod's potential as a second IDO-targeted agent in melanoma. Also higher after its earnings report was teen-focused retailer Zumiez (ZUMZ), which gained 21%. Among the noteworthy losers was American Outdoor Brands (AOBC), which dropped 17% after reporting quarterly results that were hurt by inventory destocking and a highly promotional environment for firearms. Also lower following its earnings report was grocer Kroger (KR), which fell 10%. INDEXES: Near midday, the Dow was up 53.28, or 0.24%, to 21,838.06, the Nasdaq was down 20.11, or 0.31%, to 6,377.76, and the S&P 500 was down 0.23, or 0.01%, to 2,464.87.

EFX

Equifax

$124.97

-17.755 (-12.44%)

TRU

TransUnion

$47.34

-2.05 (-4.15%)

KR

Kroger

$20.58

-2.19 (-9.62%)

AOBC

American Outdoor Brands

ZUMZ

Zumiez

$13.20

0.05 (0.38%)

NLNK

NewLink Genetics

$13.60

5.81 (74.58%)

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 28

    Sep

  • 27

    Oct

EFX Equifax
$124.97

-17.755 (-12.44%)

09/08/17
JPMS
09/08/17
NO CHANGE
JPMS
Overweight
Equifax should be bought if selloff tops 10%, says JPMorgan
JPMorgan analyst Andrew Steinerman recommends buying shares of Equifax should today's selloff on the data breach exceed 10%. The stock in premarket trading is down 15%, or $21.03, to $121.69. Importantly, Equifax's core credit reporting databases were not impacted, Steinerman tells investors in a research note after speaking to management. The company's CEO emphasized his belief that the financial impact of this incident will be isolated to the B2C segment, the analyst adds. Steinerman says his conviction in Equifax's longer term business outlook "remains steadfast." The analyst keeps an Overweight rating on the shares.
09/08/17
MACQ
09/08/17
NO CHANGE
MACQ
Beneficiaries of Equifax data breach at Macquarie
Macquarie analyst Sarah Hindlian said key beneficiaries of the Equifax (EFX) data breach are Proofpoint (PFPT) with its leading messaging solutions, Symantec (SYMC) which offers consumer identity theft services, and Imperva (IMPV) which offers web application security solutions.
09/08/17
EVER
09/08/17
NO CHANGE
Target $174
EVER
Outperform
Evercore ISI 'aggressively' buying Equifax shares amid breach weakness
Evercore ISI analyst David Togut estimates the cost to Equifax, before insurance reimbursement, from the data breach it disclosed last night could range from a low of $270M after-tax to a high of $682M, or a range from $2.24 to $5.60 per share. While large, these are one-time in nature and should not affect the long term earnings or free cash flow generation of the "excellent" business, said Togut, who would be "aggressively buying shares" amid the stock's pullback today. He reiterates an Outperform rating and $174 price target on Equifax.
09/08/17
STFL
09/08/17
NO CHANGE
Target $149
STFL
Buy
Equifax breach has $300M-$325M cost potential, says Stifel
Stifel analyst Shlomo Rosenbaum said he is not yet changing his estimates for Equifax (EFX) to account for its significant cybersecurity breach due to a lack of clarity, but added that "clearly our and the consensus estimates for 2017 and 2018 are just too high." Citing the prior large scale breaches at Target (TGT) and Home Depot (HD) as examples, Rosenbaum said $300M-$325M in gross costs would not be unreasonable for Equifax before accounting for the longer-term reputational impact and affect on existing and future customer relationships. Rosenbaum removed Equifax from the firm's Select List, but as of now has a Buy rating and $149 price target on the stock.
TRU TransUnion
$47.34

-2.05 (-4.15%)

09/08/17
DBAB
09/08/17
NO CHANGE
Target $160
DBAB
Buy
Equifax shares could close down 10% on breach, says Deutsche Bank
Deutsche Bank analyst Kevin McVeigh believes shares of Equifax (EFX) could close down 10% today after the company disclosed a security breach potentially impacting up to 143M consumers. The stock in premarket trading is down 13%, or $18.72, to $124.00. The analyst says that while difficult to quantify, his best effort suggests the financial impact could be in the range of $300M-$400M, which reflects the costs for credit monitoring, regulatory fines and penalties. Keith recommends waiting for Equifax shares to settle before accumulating fresh positions. The analyst, however, recommends buying TransUnion (TRU) on any selloff in sympathy to Equifax. He thinks TransUnion could trade down 3%-5% today before rebounding. Keith has a Buy rating on Equifax with a $160 price target.
06/28/17
BARD
06/28/17
NO CHANGE
Target $48
BARD
Outperform
TransUnion guidance remains conservative, says Baird
Baird analyst Jeffrey Mueler hosted investor meetings for TransUnion and continues to view it as a company with a long growth runway and sizable untapped addressable market. The analyst sees many growth drivers that are in the early to middle stages of monetization so he expects strong growth with strong margin expansion to continue. He believes guidance and estimates remain conservative. Meuler reiterated his Outperform rating and raised his price target to $48 from $46 on TransUnion shares.
09/06/17
09/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Caterpillar (CAT) initiated with a Neutral at Seaport Global. 2. Liberty Global (LBTYA) initiated with a Buy at Deutsche Bank. 3. TransUnion (TRU) initiated with a Buy at SunTrust. 4. Inovio (INO) initiated with a Buy at Citi. 5. e.l.f. Beauty (ELF) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/17
RHCO
09/05/17
INITIATION
Target $54
RHCO
Buy
TransUnion initiated with a Buy at SunTrust
SunTrust analyst Andrew Jeffrey started TransUnion with a Buy rating and $54 price target. The analyst expects share gains to drive greater than peer revenue growth and margin expansion.
KR Kroger
$20.58

-2.19 (-9.62%)

09/08/17
09/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Neutral on declining US beverage sales at Credit Suisse with analyst Laurent Grandet saying risk/reward is "balanced" following an 11% share appreciation over the past year, especially with US beverage sales struggling year-to-date. 2. Chipotle (CMG) downgraded to Underperform from Market Perform at Cowen with analyst Andrew Charles citing proprietary survey data that indicates the company's quality and value perceptions remain at trough levels, leading him to believe the sales recovery will continue to trail investor expectations. 3. Aflac (AFL) downgraded to Underperform from Neutral at BofA/Merrill with analyst Seth Weiss citing relative valuation. 4. Kroger (KR) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh citing the company's second quarter results. 5. Rice Energy (RICE) downgraded to Neutral from Buy at Goldman Sachs with analyst Brian Singer citing valuation following recent outperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
OPCO
09/08/17
DOWNGRADE
OPCO
Perform
Kroger downgraded to Perform from Outperform at Oppenheimer
09/08/17
OPCO
09/08/17
DOWNGRADE
Target $23
OPCO
Perform
Oppenheimer downgrades Kroger to Perform post earnings
Oppenheimer analyst Rupesh Parikh downgraded Kroger to Perform from Outperform following this morning's Q2 results. Management's forward commentary "was more muted" than expectations and suggests the potential for a second half of 2017 comp increase of just 0.5%-1.0%, Parikh tells investors in a research note. He believes the case for share outperformance is now more difficult and cut his price target for the shares to $23 from $28. The stock in premarket trading is down 7% to $21.25.
08/29/17
CLVD
08/29/17
NO CHANGE
CLVD
Neutral
Kroger Q2 sales likely slightly above consensus, says Cleveland Research
Cleveland Research analyst Scott Bender said Kroger Q2 sales trends appear better versus Q1 and slightly above cosensus due to some volume improvement and less deflation. The analyst rates Kroger a Neutral.
AOBC American Outdoor Brands

09/08/17
LSCM
09/08/17
NO CHANGE
Target $13
LSCM
Hold
American Outdoor Brands price target lowered to $13 from $17 at Lake Street
Lake Street analyst Chris Krueger lowered his price target for American Outdoor Brands to $13 saying the company's Q1 results "were weak" despite giving guidance with just four weeks remaining in the quarter. The analyst believes trends fell off in July and have remained weak thus far in Q2. He thinks the industry environment will remain difficult for several more months and keeps a Hold rating on the shares.
09/08/17
CHLM
09/08/17
NO CHANGE
Target $15
CHLM
Hold
American Outdoor Brands price target lowered to $15 from $23 at Craig-Hallum
Craig-Hallum analyst Steven Dyer noted that inventory destocking and a highly promotional environment hurt American Outdoor Brands' sales and margins and he believes it is too early to say the worst is past for the firearms industry. He keeps a Hold rating on American Outdoor shares and lowered his price target on the stock to $15 from $23.
08/21/17
AGIS
08/21/17
INITIATION
Target $25
AGIS
Buy
American Outdoor Brands initiated with a Buy at Aegis
Aegis analyst Rommel Dionisio initiated American Outdoor Brands with a Buy and a $25 price target.
09/01/17
IFSG
09/01/17
INITIATION
Target $21
IFSG
Outperform
American Outdoor Brands initiated with an Outperform at IFS Securities
IFS Securities analyst Ronald Bookbinder started American Outdoor Brands with an Outperform rating and $21 price target. The analyst sees an "excellent investment opportunity" given the company's focus on taking market share and developing new products.
ZUMZ Zumiez
$13.20

0.05 (0.38%)

12/22/16
RILY
12/22/16
DOWNGRADE
RILY
Neutral
Zumiez downgraded to Neutral from Buy at B. Riley
12/22/16
RILY
12/22/16
DOWNGRADE
Target $25
RILY
Neutral
Zumiez downgraded to Neutral from Buy at B. Riley
B. Riley analyst Jeff Van Sinderen downgraded Zumiez to Neutral and lowered his price target for the shares to $25 from $27. The analyst cites his reduced EBITDA multiple for the downgrade.
09/08/17
09/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zumiez (ZUMZ) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen citing the company's second quarter results. 2. Ralph Lauren (RL) upgraded to Outperform from Neutral at Credit Suisse. 3. Realty Income (O) upgraded to Neutral from Sell at UBS. 4. MAA (MAA) upgraded to Buy from Neutral at BTIG with analyst James Sullivan saying the company's integration of Post is accretive and is going smoothly. 5. STAG Industrial (STAG) upgraded to Neutral from Sell at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
RILY
09/08/17
UPGRADE
Target $18
RILY
Buy
Zumiez upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Zumiez to Buy following the company's Q2 results and raised his price target for the shares to $18 from $17.
NLNK NewLink Genetics
$13.60

5.81 (74.58%)

09/08/17
JEFF
09/08/17
UPGRADE
Target $26
JEFF
Buy
NewLink Genetics upgraded to Buy from Hold at Jefferies
Jefferies analyst Biren Amin upgraded NewLink Genetics to Buy and raised his price target for the shares to $26 from $7. The analyst sees additional share upside post the ongoing Phase II trial update given indoximod's potential as a second IDO-targeted agent in melanoma. The indoximod combo appears comparable to the Epacadostat combo in melanoma, Amin tells investors in a research note.
06/09/17
RHCO
06/09/17
NO CHANGE
RHCO
NewLink Genetics shares undervalued after Roche move, says SunTrust
After Roche (RHBBY) returned GDC-0919 to NewLink (NLNK), SunTrust analyst Peter Lawson says that NewLink "is undervalued." The analyst says that Roche's decision won't affect NewLink's indoximod, which he thinks could generate $400M in peak sales. He adds that '919 has shown some signs of modest efficacy and could still produce value over the next year. The analyst cut his price target on NewLink to $19 from $30 but keeps a Buy rating on the stock.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Incyte, NewLink have positive read through from trial failure, says SunTrust
SunTrust analyst PEter Lawson says that the failure of AstraZeneca's (AZN) PD-L1/CTLA4 combo to hit its progression free survival primary endpoint is positive for Incyte (INCY) and NewLink (NLNK0. The analyst says that the failure "relives a competitive concern" for the companies. He keeps a $145 price target and a Buy rating on Incyte.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.

TODAY'S FREE FLY STORIES

02:30
01/19/18
01/19
02:30
01/19/18
02:30
General news
FX Update: The dollar has traded softer on U.S. political concerns »

FX Update: The dollar…

01:50
01/19/18
01/19
01:50
01/19/18
01:50
General news
FX Action: USD-JPY has traded moderately softer »

FX Action: USD-JPY has…

COLD

Americold Realty Trust

20:35
01/18/18
01/18
20:35
01/18/18
20:35
Syndicate
Americold Realty Trust 45.3M share IPO priced at $16.00 »

The company sold 29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HTGM

HTG Molecular

$3.40

0.54 (18.88%)

20:29
01/18/18
01/18
20:29
01/18/18
20:29
Syndicate
HTG Molecular 12M share Secondary priced at $2.90 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

NINE

Nine Energy Services

20:27
01/18/18
01/18
20:27
01/18/18
20:27
Syndicate
Nine Energy Services 7M share IPO priced at $23.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

, STI

SunTrust

$67.94

-0.41 (-0.60%)

20:25
01/18/18
01/18
20:25
01/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

STI

SunTrust

$67.94

-0.41 (-0.60%)

SYF

Synchrony

$37.30

-0.76 (-2.00%)

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

RF

Regions Financial

$18.15

-0.21 (-1.14%)

KSU

Kansas City Southern

$111.50

0.69 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

URGN

UroGen Pharma

$42.46

-0.8 (-1.85%)

19:12
01/18/18
01/18
19:12
01/18/18
19:12
Syndicate
UroGen Pharma 1.463M share Secondary priced at $41.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

ADT

ADT Inc.

19:10
01/18/18
01/18
19:10
01/18/18
19:10
Syndicate
ADT Inc. 105M share IPO priced at $17.00-19.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

18:47
01/18/18
01/18
18:47
01/18/18
18:47
Periodicals
House Freedom Caucus to support bill preventing government shutdown, AP says 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

18:39
01/18/18
01/18
18:39
01/18/18
18:39
Periodicals
BNY Mellon to boost wages for 1,000 workers after tax reform, WSJ says »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Mar

TRNC

tronc

$19.23

0.22 (1.16%)

18:28
01/18/18
01/18
18:28
01/18/18
18:28
Periodicals
tronc to investigate LA Times' CEO Ross Levinsohn, Financial Times reports »

tronc has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

18:19
01/18/18
01/18
18:19
01/18/18
18:19
Hot Stocks
IBM's Schroeter says mainframe isn't going away »

IBM senior VP of Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ATR

AptarGroup

$87.24

0.4 (0.46%)

18:16
01/18/18
01/18
18:16
01/18/18
18:16
Hot Stocks
AptarGroup chairman King Harris to retire in May »

AptarGroup chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 27

    Apr

  • 02

    May

  • 27

    Jul

  • 26

    Oct

FULT

Fulton Financial

$18.30

-0.25 (-1.35%)

18:12
01/18/18
01/18
18:12
01/18/18
18:12
Hot Stocks
Fulton Financial to raise its minimum wage to $12 per hour »

Fulton Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SNAP

Snap

$14.01

0.49 (3.62%)

18:03
01/18/18
01/18
18:03
01/18/18
18:03
Periodicals
Snap fires roughly two dozen employees, Cheddar reports »

Snap Inc. has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 06

    Feb

  • 07

    Feb

PAVM

PAVmed

$2.54

-0.02 (-0.78%)

17:57
01/18/18
01/18
17:57
01/18/18
17:57
Syndicate
PAVmed files to sell common stock, no amount given »

Dawson James Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PODD

Insulet

$72.89

-0.02 (-0.03%)

, DXCM

Dexcom

$56.28

-0.04 (-0.07%)

17:51
01/18/18
01/18
17:51
01/18/18
17:51
Recommendations
Insulet, Dexcom, TNDM, Medtronic analyst commentary at Piper Jaffray »

Insulet is a favored…

PODD

Insulet

$72.89

-0.02 (-0.03%)

DXCM

Dexcom

$56.28

-0.04 (-0.07%)

TNDM

TNDM

MDT

Medtronic

$87.26

1.15 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

17:50
01/18/18
01/18
17:50
01/18/18
17:50
General news
Breaking General news story  »

Cleveland Federal Reserve…

IBM

IBM

$169.12

0.47 (0.28%)

17:39
01/18/18
01/18
17:39
01/18/18
17:39
Earnings
Breaking Earnings news story on IBM »

IBM sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

17:38
01/18/18
01/18
17:38
01/18/18
17:38
Initiation
Trade Desk initiated at Stifel »

Trade Desk initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.04

-0.52 (-2.12%)

, FB

Facebook

$179.80

2.2 (1.24%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Hot Stocks
Snap user metrics being put into question by Mashable, Muddy Waters »

After the close, Mashable…

TWTR

Twitter

$24.04

-0.52 (-2.12%)

FB

Facebook

$179.80

2.2 (1.24%)

SNAP

Snap

$14.01

0.49 (3.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

TWTR

Twitter

$24.04

-0.52 (-2.12%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Recommendations
Twitter analyst commentary at Stifel »

Twitter coverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Hot Stocks
Breaking Hot Stocks news story on IBM »

IBM sees FY18 free cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Earnings
IBM sees Q1 EPS 17%-18% of $13.80 FY expectation, consensus $2.28 »

Says has momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ZG

Zillow

$43.86

-0.49 (-1.10%)

, Z

Zillow

$43.97

-0.57 (-1.28%)

17:33
01/18/18
01/18
17:33
01/18/18
17:33
Downgrade
Zillow, Zillow rating change at Stifel »

Zillow resumed with a…

ZG

Zillow

$43.86

-0.49 (-1.10%)

Z

Zillow

$43.97

-0.57 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.